INTERNATIONAL VACCINE INSTITUTE

Address
snu research park 1 gwanak-ro
seoul, FO 151-742
KS
Contact
Website: http://www.ivi.int
Phone: +1 (822) 872-2803
Nonprofit
NTEE: Q053 - International, foreign affairs and national security
EIN: 31-1621592

Mission

SEE SCHEDULE O
 201720162015
Basic features of the organization
Year of formation1997
Subsection501(c)(3)
Organization typeAssociation
Human resources, including compensation
Summary compensation info
Total compensation of current key personnel$4,893,419.00$4,533,355.00$1,762,057.00
Sum of reportable (W2/1099) compensation$2,797,360.00$2,630,915.00$1,792,874.00
Number of employees100
Number of people compensated >$100k192110
Number of volunteers766
Number of highly compensated contractors122
Personnel
Balow, Ros-Mari
TitleDirector / Board of Trustee  
Name of key/compensated personROS-MARI BALOW  
Average hours per week working for org1.0  
Reportable compensation from org$0.00  
Other comp, non-reportable, from org and related orgs$0.00  
PositionIndividual trustee or director  
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00  
Average hours per week working for related orgs0.0  
Bickerstaff, George
TitleDirector / Board of TrusteeDirector / Board of TrusteeDirector / Board of Trustee
Name of key/compensated personGeorge BickerstaffGeorge BickerstaffGeorge Bickerstaff
Average hours per week working for org1.01.01.0
Reportable compensation from org$796.00$1,250.00$1,684.00
Other comp, non-reportable, from org and related orgs$0.00$0.00$0.00
PositionIndividual trustee or directorIndividual trustee or directorIndividual trustee or director
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00$0.00
Average hours per week working for related orgs0.00.00.0
Binka, Fred
TitleDirector / Board of TrusteeDirector / Board of TrusteeDirector / Board of Trustee
Name of key/compensated personFred BinkaFred BinkaFred Binka
Average hours per week working for org1.01.01.0
Reportable compensation from org$1,776.00$796.00$934.00
Other comp, non-reportable, from org and related orgs$0.00$0.00$0.00
PositionIndividual trustee or directorIndividual trustee or directorIndividual trustee or director
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00$0.00
Average hours per week working for related orgs0.00.00.0
Carbis, Rodney
Title  Head, Vaccine Development Depa
Name of key/compensated person  Rodney Carbis
Average hours per week working for org  40.0
Reportable compensation from org  $203,762.00
Other comp, non-reportable, from org and related orgs  $12,294.00
Position  Highly compensated employee
Corresponding comp from related orgs
Reportable compensation from related orgs   $0.00
Average hours per week working for related orgs  0.0
Chon, Yun
TitleHead of Biostatistics & Data  
Name of key/compensated personYun Chon  
Average hours per week working for org40.0  
Reportable compensation from org$217,822.00  
Other comp, non-reportable, from org and related orgs$36,753.00  
PositionHighly compensated employee  
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00  
Average hours per week working for related orgs0.0  
Digilio, Laura
Title Deputy Dir. Gen of Dev & DelivDeputy Director General of Dev
Name of key/compensated person Laura DigilioLaura Digilio
Average hours per week working for org 40.040.0
Reportable compensation from org $274,557.00$175,073.00
Other comp, non-reportable, from org and related orgs $6,804.00$14,349.00
Position Key employeeOfficer
Corresponding comp from related orgs
Reportable compensation from related orgs  $0.00$0.00
Average hours per week working for related orgs 0.00.0
Diorditsa, Sergey
Title Director / Board of Trustee 
Name of key/compensated person Sergey Diorditsa 
Average hours per week working for org 1.0 
Reportable compensation from org $796.00 
Other comp, non-reportable, from org and related orgs $0.00 
Position Individual trustee or director 
Corresponding comp from related orgs
Reportable compensation from related orgs  $0.00 
Average hours per week working for related orgs 0.0 
Driver, Phil
TitleDeputy Dir. Gen of Fin & OpsDeputy Dir. Gen of Fin & OPS 
Name of key/compensated personPhil DriverPhil Driver 
Average hours per week working for org40.040.0 
Reportable compensation from org$331,661.00$329,139.00 
Other comp, non-reportable, from org and related orgs$3,919.00$7,543.00 
PositionOfficerOfficer 
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00 
Average hours per week working for related orgs0.00.0 
Eskola, Juhani
Title  Director / Board of Trustee
Name of key/compensated person  Juhani Eskola
Average hours per week working for org  1.0
Reportable compensation from org  $796.00
Other comp, non-reportable, from org and related orgs  $0.00
Position  Individual trustee or director
Corresponding comp from related orgs
Reportable compensation from related orgs   $0.00
Average hours per week working for related orgs  0.0
Excler, Jean-Louis
TitleHead of Clinical Dev & Reg.Head of Clinical Dev & Reg 
Name of key/compensated personJean-Louis ExclerJean-Louis Excler 
Average hours per week working for org40.040.0 
Reportable compensation from org$221,133.00$222,587.00 
Other comp, non-reportable, from org and related orgs$8,210.00$5,904.00 
PositionHighly compensated employeeHighly compensated employee 
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00 
Average hours per week working for related orgs0.00.0 
Garcia, Romulo
Title  Director / Board of Trustee
Name of key/compensated person  Romulo Garcia
Average hours per week working for org  1.0
Reportable compensation from org  $842.00
Other comp, non-reportable, from org and related orgs  $0.00
Position  Individual trustee or director
Corresponding comp from related orgs
Reportable compensation from related orgs   $0.00
Average hours per week working for related orgs  0.0
Gupta, Vinay
Title  Chief, IT Team
Name of key/compensated person  Vinay Kumar Gupta
Average hours per week working for org  40.0
Reportable compensation from org  $134,874.00
Other comp, non-reportable, from org and related orgs  $22,124.00
Position  Highly compensated employee
Corresponding comp from related orgs
Reportable compensation from related orgs   $0.00
Average hours per week working for related orgs  0.0
Han, Kyung-Taik
TitleDeputy Dir. Gen of Gov Affairs  
Name of key/compensated personKyung-Taik Han  
Average hours per week working for org40.0  
Reportable compensation from org$209,706.00  
Other comp, non-reportable, from org and related orgs$774.00  
PositionHighly compensated employee  
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00  
Average hours per week working for related orgs0.0  
Hong, Deborah
Title Head of PR & CommHead of the Communications and
Name of key/compensated person Deborah Gene HongDeborah Gene Hong
Average hours per week working for org 40.040.0
Reportable compensation from org $188,459.00$156,083.00
Other comp, non-reportable, from org and related orgs $1,510.00$25,567.00
Position Highly compensated employeeOfficer
Corresponding comp from related orgs
Reportable compensation from related orgs  $0.00$0.00
Average hours per week working for related orgs 0.00.0
Hyung, Lee
TitleDirector / Board of TrusteeDirector / Board of Trustee 
Name of key/compensated personLee Kyu HyungLee Kyu Hyung 
Average hours per week working for org1.01.0 
Reportable compensation from org$750.00$1,319.00 
Other comp, non-reportable, from org and related orgs$0.00$0.00 
PositionIndividual trustee or directorIndividual trustee or director 
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00 
Average hours per week working for related orgs0.00.0 
Jangkeun, Lee
TitleDirector / Board of TrusteeDirector / Board of Trustee 
Name of key/compensated personLEE JANGKEUNLee Jangkeun 
Average hours per week working for org1.01.0 
Reportable compensation from org$0.00$0.00 
Other comp, non-reportable, from org and related orgs$0.00$0.00 
PositionIndividual trustee or directorIndividual trustee or director 
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00 
Average hours per week working for related orgs0.00.0 
Jong, Yoo
Title  Director / Board of Trustee
Name of key/compensated person  Yoo Dae Jong
Average hours per week working for org  1.0
Reportable compensation from org  $1,500.00
Other comp, non-reportable, from org and related orgs  $0.00
Position  Individual trustee or director
Corresponding comp from related orgs
Reportable compensation from related orgs   $0.00
Average hours per week working for related orgs  0.0
Kim, Jerome
TitleDirector GeneralDirector GeneralDirector General
Name of key/compensated personJerome KimJerome KimJerome Kim
Average hours per week working for org40.01.040.0
Reportable compensation from org$651,772.00$503,711.00$338,523.00
Other comp, non-reportable, from org and related orgs$149,211.00$138,870.00$51,274.00
PositionIndividual trustee or director, OfficerIndividual trustee or director, OfficerIndividual trustee or director, Officer
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00$0.00
Average hours per week working for related orgs0.00.00.0
Kim, Joseph
TitleDirector / Board of TrusteeDirector / Board of TrusteeDirector / Board of Trustee
Name of key/compensated personJoseph KimJoseph KimJoseph Kim
Average hours per week working for org1.01.01.0
Reportable compensation from org$1,638.00$1,250.00$1,592.00
Other comp, non-reportable, from org and related orgs$0.00$0.00$0.00
PositionIndividual trustee or directorIndividual trustee or directorIndividual trustee or director
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00$0.00
Average hours per week working for related orgs0.00.00.0
Kothari, Sudeep
Title Senior Research ScientistResearch Scientist
Name of key/compensated person Sudeep KothariSudeep Kothari
Average hours per week working for org 40.040.0
Reportable compensation from org $178,807.00$139,484.00
Other comp, non-reportable, from org and related orgs $1,460.00$20,396.00
Position Highly compensated employeeHighly compensated employee
Corresponding comp from related orgs
Reportable compensation from related orgs  $0.00$0.00
Average hours per week working for related orgs 0.00.0
Lynch, Julia
TitleDeputy Dir. Gen of Dev & delvyDeputy Dir. Gen of Dev & Delvy 
Name of key/compensated personJulia LynchJulia Lynch 
Average hours per week working for org40.040.0 
Reportable compensation from org$389,071.00$179,401.00 
Other comp, non-reportable, from org and related orgs$60,344.00$42,997.00 
PositionKey employeeKey employee 
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00 
Average hours per week working for related orgs0.00.0 
Mahmoud, Adel
TitleChairman / Board of TrusteeChairman / Board of TrusteeChairman / Board of Trustee
Name of key/compensated personAdel AF MahmoudAdel AF MahmoudAdel AF Mahmoud
Average hours per week working for org1.01.01.0
Reportable compensation from org$750.00$500.00$1,638.00
Other comp, non-reportable, from org and related orgs$0.00$0.00$0.00
PositionIndividual trustee or directorIndividual trustee or directorIndividual trustee or director
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00$0.00
Average hours per week working for related orgs0.00.00.0
Mehendale, Sanjay
TitleDirector / Board of Trustee  
Name of key/compensated personSANJAY MADHAV MEHENDALE  
Average hours per week working for org1.0  
Reportable compensation from org$0.00  
Other comp, non-reportable, from org and related orgs$0.00  
PositionIndividual trustee or director  
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00  
Average hours per week working for related orgs0.0  
Morahan, John
Title  Deputy Director General of Fin
Name of key/compensated person  John Morahan
Average hours per week working for org  40.0
Reportable compensation from org  $253,514.00
Other comp, non-reportable, from org and related orgs  $28,788.00
Position  Officer
Corresponding comp from related orgs
Reportable compensation from related orgs   $0.00
Average hours per week working for related orgs  0.0
Nohynek, Hanna
TitleDirector / Board of TrusteeDirector / Board of Trustee 
Name of key/compensated personHanna NohynekHanna Nohynek 
Average hours per week working for org1.01.0 
Reportable compensation from org$1,638.00$1,399.00 
Other comp, non-reportable, from org and related orgs$0.00$0.00 
PositionIndividual trustee or directorIndividual trustee or director 
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00 
Average hours per week working for related orgs0.00.0 
Pavliak, Viliam
TitleHead of Vaccine Process DevHead, Vaccine Dev Dept 
Name of key/compensated personViliam PavliakViliam Pavliak 
Average hours per week working for org40.040.0 
Reportable compensation from org$264,022.00$236,340.00 
Other comp, non-reportable, from org and related orgs$46,120.00$65,998.00 
PositionHighly compensated employeeHighly compensated employee 
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00 
Average hours per week working for related orgs0.00.0 
Persson, Viveka
Title Director / Board of Trustee 
Name of key/compensated person Viveka Persson 
Average hours per week working for org 1.0 
Reportable compensation from org $0.00 
Other comp, non-reportable, from org and related orgs $0.00 
Position Individual trustee or director 
Corresponding comp from related orgs
Reportable compensation from related orgs  $0.00 
Average hours per week working for related orgs 0.0 
Sahastrabuddhe, Sushant
Title  Program Leader of EDD and Head
Name of key/compensated person  Sushant Sahastrabuddhe
Average hours per week working for org  40.0
Reportable compensation from org  $126,060.00
Other comp, non-reportable, from org and related orgs  $22,562.00
Position  Highly compensated employee
Corresponding comp from related orgs
Reportable compensation from related orgs   $0.00
Average hours per week working for related orgs  0.0
Siber, George
TitleDirector / Board of TrusteeDirector / Board of TrusteeDirector / Board of Trustee
Name of key/compensated personGeorge SiberGeorge SiberGeorge Siber
Average hours per week working for org1.01.01.0
Reportable compensation from org$1,546.00$1,342.00$1,684.00
Other comp, non-reportable, from org and related orgs$0.00$0.00$0.00
PositionIndividual trustee or directorIndividual trustee or directorIndividual trustee or director
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00$0.00
Average hours per week working for related orgs0.00.00.0
Song, Manki
TitleHead of Clinical Research LabHead of Clinical Research LabSenior Research Scientist
Name of key/compensated personManki SongManki SongManki Song
Average hours per week working for org40.040.040.0
Reportable compensation from org$193,399.00$182,545.00$151,950.00
Other comp, non-reportable, from org and related orgs$4,025.00$3,784.00$25,707.00
PositionHighly compensated employeeHighly compensated employeeHighly compensated employee
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00$0.00
Average hours per week working for related orgs0.00.00.0
Sweeney, Malcolm
TitleDirector / Board of Trustee  
Name of key/compensated personMALCOLM SWEENEY  
Average hours per week working for org1.0  
Reportable compensation from org$0.00  
Other comp, non-reportable, from org and related orgs$0.00  
PositionIndividual trustee or director  
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00  
Average hours per week working for related orgs0.0  
Varma, Chris
TitleDirector / Board of Trustee  
Name of key/compensated personCHRIS VARMA  
Average hours per week working for org1.0  
Reportable compensation from org$0.00  
Other comp, non-reportable, from org and related orgs$0.00  
PositionIndividual trustee or director  
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00  
Average hours per week working for related orgs0.0  
Yoon, In
TitleProgram Director, MERS and GDADeputy Director General of SciDeputy Director General of Sci
Name of key/compensated personIn Kyu YoonIn Kyu YoonIn Kyu Yoon
Average hours per week working for org40.040.040.0
Reportable compensation from org$308,380.00$325,329.00$102,881.00
Other comp, non-reportable, from org and related orgs$72,590.00$76,760.00$17,921.00
PositionKey employeeKey employeeOfficer
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00$0.00
Average hours per week working for related orgs0.00.00.0
Youngmee, Jee
TitleDirector / Board of TrusteeDirector / Board of Trustee 
Name of key/compensated personJee YoungmeeJee Youngmee 
Average hours per week working for org1.01.0 
Reportable compensation from org$1,500.00$1,388.00 
Other comp, non-reportable, from org and related orgs$0.00$0.00 
PositionIndividual trustee or directorIndividual trustee or director 
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00 
Average hours per week working for related orgs0.00.0 
Youngsoo, Shin
TitleDirector / Board of Trustee  
Name of key/compensated personSHIN YOUNGSOO  
Average hours per week working for org1.0  
Reportable compensation from org$0.00  
Other comp, non-reportable, from org and related orgs$0.00  
PositionIndividual trustee or director  
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00  
Average hours per week working for related orgs0.0  
Purpose: mission, activities & accomplishments
Mission or significant activitiesSEE SCHEDULE OSEE SCHEDULE OIVI's mission is to discover, develop and deliver safe, effective DELIVER SAFE, EFFECTIVE AND AFFORDABLE VACCINES FOR THE WORLD'S DEVELOPING NATIONS.
Program expenses (total)$21,409,516.00$20,009,212.00$16,634,140.00
Programs, including revenue & expenses
Cholera OCV: The studys objective is to evaluate the efficacy and safety of a single dose regimen of the modified killed oral cholera vaccine. An individually randomized, placebo controlled trial to measure single dose efficacy was initiated in January 2014. The vaccine efficacy of six-month follow-up was 40% against all cholera and 63% against severely dehydrated cholera. The paper of six-month follow-up has been published by the New England Journal of Medicine in May 2016*. The follow up for one year and its data analysis have been completed in 2015 and the manuscript of one-year data is preparing. Surveillance continues to complete 2 years of follow-up.
Program expenses  $1,355,903.00
Grants and allocations made  $750,000.00
Program description  Cholera OCV: The studys objective is to evaluate the efficacy and safety of a single dose regimen of the modified killed oral cholera vaccine. An individually randomized, placebo controlled trial to measure single dose efficacy was initiated in January 2014. The vaccine efficacy of six-month follow-up was 40% against all cholera and 63% against severely dehydrated cholera. The paper of six-month follow-up has been published by the New England Journal of Medicine in May 2016*. The follow up for one year and its data analysis have been completed in 2015 and the manuscript of one-year data is preparing. Surveillance continues to complete 2 years of follow-up.
Dengue Vaccine Initiative (DVI) One of major strides made in 2016 under Dengue program is the creation of Global Dengue Prevention and Control Consortium (GADC). In recognition for the need for a comprehensive approach including vaccine and vector control, the Dengue Vaccine Initiative (DVI) hosted by IVI and the Partnership for Dengue Control Foundation (PDC) merged to form GDAC on 31 August 2016. In 2016, DVI continued the activities to pave the way for introduction of dengue vaccine through evidence generation, policy and access, regulatory, and advocacy activities. DVI conducted studies on dengue disease and economic burden through field studies in Thailand, Vietnam, Cambodia, Colombia, Burkina Faso, Gabon, and Kenya; continued surveillance, serological surveys, and cost-of-illness survey in these countries; and started to perform various laboratory tests and analysis. Preliminary results from studies were shared and discussed at the Field Investigators meeting in February 2016. DVI/GDAC convened the Dengue Prevention Board Meetings in Malaysia and Mexico, for the Asia Pacific and American region respectively. The meeting focused on providing specific points of considerations in light of the WHO SAGE recommendations on dengue vaccine introduction released in April 2016. DVI/GDAC also convened a meeting of national regulatory authorities (NRAs) from dengue endemic countries in conjunction with WHOs Developing Country Vaccine Regulators Network (DCVRN) meeting in Brazil in November 2016 and discussed regulatory approvals for dengue vaccines for the initial seven countries as well as the 2nd wave countries.
Program expenses $2,465,139.00 
Grants and allocations made $930,390.00 
Program description Dengue Vaccine Initiative (DVI) One of major strides made in 2016 under Dengue program is the creation of Global Dengue Prevention and Control Consortium (GADC). In recognition for the need for a comprehensive approach including vaccine and vector control, the Dengue Vaccine Initiative (DVI) hosted by IVI and the Partnership for Dengue Control Foundation (PDC) merged to form GDAC on 31 August 2016. In 2016, DVI continued the activities to pave the way for introduction of dengue vaccine through evidence generation, policy and access, regulatory, and advocacy activities. DVI conducted studies on dengue disease and economic burden through field studies in Thailand, Vietnam, Cambodia, Colombia, Burkina Faso, Gabon, and Kenya; continued surveillance, serological surveys, and cost-of-illness survey in these countries; and started to perform various laboratory tests and analysis. Preliminary results from studies were shared and discussed at the Field Investigators meeting in February 2016. DVI/GDAC convened the Dengue Prevention Board Meetings in Malaysia and Mexico, for the Asia Pacific and American region respectively. The meeting focused on providing specific points of considerations in light of the WHO SAGE recommendations on dengue vaccine introduction released in April 2016. DVI/GDAC also convened a meeting of national regulatory authorities (NRAs) from dengue endemic countries in conjunction with WHOs Developing Country Vaccine Regulators Network (DCVRN) meeting in Brazil in November 2016 and discussed regulatory approvals for dengue vaccines for the initial seven countries as well as the 2nd wave countries. 
Severe Typhoid in Africa(SETA) SETA is a follow-up grant of TSAP funded by The Bill and Melinda Gates Foundation. It aims to estimate the burden, severity, immune response, long-term sequelae and the associated costs of invasive Salmonella infections in sub-Saharan Africa. Network of surveillance sites across 6 countries in sSA is set up and activities are on-going in all SETA countries: Madagascar (Antananarivo, Imerintsiatosika), Burkina Faso (Ouagadougou, Polesgo, Nioko), Ghana (Agogo, Kumasi), Nigeria (Ibadan), Ethiopia (Adama Wenji and Welayita Sodo), and DRC (Kisantu.) As of December 31, 2017, a total of 202,902 patients had been screened from all participating sites. From these screened patients, 5% (10,137/201,570) met the study inclusion criteria of which 76% (7,695/10,137) were enrolled in SETA
Program expenses$2,783,099.00  
Grants and allocations made$1,015,168.00  
Program descriptionSevere Typhoid in Africa(SETA) SETA is a follow-up grant of TSAP funded by The Bill and Melinda Gates Foundation. It aims to estimate the burden, severity, immune response, long-term sequelae and the associated costs of invasive Salmonella infections in sub-Saharan Africa. Network of surveillance sites across 6 countries in sSA is set up and activities are on-going in all SETA countries: Madagascar (Antananarivo, Imerintsiatosika), Burkina Faso (Ouagadougou, Polesgo, Nioko), Ghana (Agogo, Kumasi), Nigeria (Ibadan), Ethiopia (Adama Wenji and Welayita Sodo), and DRC (Kisantu.) As of December 31, 2017, a total of 202,902 patients had been screened from all participating sites. From these screened patients, 5% (10,137/201,570) met the study inclusion criteria of which 76% (7,695/10,137) were enrolled in SETA  
TSAP (Typhoid Surveillance in sub-Saharan Africa Program) - TSAP aims to generate data on the burden of typhoid fever and other invasive Salmonella infections in Africa through standardized surveillance and disease burden studies among a network of 10 African countries. The Typhoid Fever Surveillance in Africa Program (TSAP), started in 2010 and developed by the International Vaccine Institute, aims to close the data gap on invasive Salmonella infections between African and Asian countries. Surveillance activities in ten TSAP site were completed in 2014. Preliminary incidence data have been presented at different international conferences. The Bill and Melinda Gates Foundation awarded a follow-up grant at the end 2013. The purpose of this new grant is to: (1) develop and validate a risk and typhoid burden prediction model for sub-Saharan Africa, (2) investigate and define the incidence of typhoid fever in four sites in sub-Saharan Africa selected using the model, and (3) assess water quality at the African sites. Following the completed surveillance in all 13 TSAP sites in 10 countries, the data cleaning and analysis is conducted in 2015. As a result, 15 TSAP papers are published in CID. In March 2016, TSAP Supplement publication was issued for Clinical Infectious Diseases. Severe Typhoid in Africa Program (SETA) pilot study was completed in 3 sites (Ghana, Madagascar, Ethiopia). SETA main surveillance started in 3 sites (Ghana, Madagascar, Burkina Faso). And new sites selected in two new SETA countries (Nigeria, Democratic Republic of Congo).
Program expenses $2,622,991.00$2,042,858.00
Grants and allocations made $757,570.00$497,627.00
Program description TSAP (Typhoid Surveillance in sub-Saharan Africa Program) - TSAP aims to generate data on the burden of typhoid fever and other invasive Salmonella infections in Africa through standardized surveillance and disease burden studies among a network of 10 African countries. The Typhoid Fever Surveillance in Africa Program (TSAP), started in 2010 and developed by the International Vaccine Institute, aims to close the data gap on invasive Salmonella infections between African and Asian countries. Surveillance activities in ten TSAP site were completed in 2014. Preliminary incidence data have been presented at different international conferences. The Bill and Melinda Gates Foundation awarded a follow-up grant at the end 2013. The purpose of this new grant is to: (1) develop and validate a risk and typhoid burden prediction model for sub-Saharan Africa, (2) investigate and define the incidence of typhoid fever in four sites in sub-Saharan Africa selected using the model, and (3) assess water quality at the African sites. Following the completed surveillance in all 13 TSAP sites in 10 countries, the data cleaning and analysis is conducted in 2015. As a result, 15 TSAP papers are published in CID. In March 2016, TSAP Supplement publication was issued for Clinical Infectious Diseases. Severe Typhoid in Africa Program (SETA) pilot study was completed in 3 sites (Ghana, Madagascar, Ethiopia). SETA main surveillance started in 3 sites (Ghana, Madagascar, Burkina Faso). And new sites selected in two new SETA countries (Nigeria, Democratic Republic of Congo).Typhoid Surveillance in sub-Saharan Africa Program: TSAP aims to generate data on the burden of typhoid fever and other invasive Salmonella infections in Africa through standardized surveillance and disease burden studies among a network of 10 African countries. Comparable and contemporary population-based data on Salmonella spp. Infections in sub-Saharan Africa (sSA) are lacking and data, collected systematically, are urgently needed to make evidence-based decisions on the introduction of existent and upcoming vaccines against typhoid (TF)/paratyphoid fever, and non-typhoidal Salmonella (NTS) infections. The Typhoid Fever Surveillance in Africa Program (TSAP), started in 2010 and developed by the International Vaccine Institute, aims to close the data gap on invasive Salmonella infections between African and Asian countries. Accordingly, systematic and standardized passive surveillance and diagnostics of febrile patients by haemoculture were established at various sites in sSA. Since results are harmonized across study sites, incidences are comparable across. Secondary outcomes of TSAP include evaluation of antimicrobial resistance patterns and the identification of carriers of Salmonella spp. Participating countries are Guinea Bissau, Senegal, Burkina Faso, Ghana, Sudan, Ethiopia, Kenya, Tanzania, Madagascar, and South Africa. In 2013, nine of the ten TSAP sites completed surveillance activities; the site in Ethiopia completed activities in January 2014. All sites are closed. Preliminary incidence data have been presented at different international conferences (i.e. Vaccines for Enteric Diseases (VED), Bangkok, Nov 2013; American Society for Tropical Medicine and Hygiene (ASTMH), Washington DC, Nov 2013). Blood specimen are currently being investigated further at the Sanger Institute in Cambridge, UK to determine strain relatedness and molecular drug resistance paramenters. The Bill and Melinda Gates Foundation awarded a follow-up grant at the end 2013. The purpose of this new grant is to: (1) develop and validate a risk and typhoid burden prediction model for sub-Saharan Africa, (2) investigate and define the incidence of typhoid fever in four sites in sub-Saharan Africa selected using the model, and (3) assess water quality at the African sites. Following the completed surveillance in all 13 TSAP sites in 10 countries, the data cleaning and analysis is conducted in 2015. As a result, 15 TSAP papers are published in CID. The shipping process of all TSAP samples also started. They will be kept in IVI for further tests.
The Cholera Vaccine Initiative (CHOVI) 3 project activities carried out in 2016 under CHOVI grant. Firstly, Euvichol : A bridging study to evaluate the safety and immunogenicity of thimerosal-free Euvichol produced in a 600L fermenter was conducted in 2016. The study started in May 2016, and a total of 442 participants were enrolled in this study. WHO PQ was obtained for 100L Euvichol in December 2015 and for 600L Euvichol without thiomersal in September 2016 respectively. Secondly, Cholvax trial and GMP support for Incepta : Production of 3 lots completed in March 2016. The study was started in May 2016, and enrolled a total of 2,052 participants from May to October 2016. Day 42 safety follow-up was completed in November 2016. Thirdly, Cholera surveillance in Malawi: Cholera surveillance is embarked in April 2016. Series of trainings such as lab trainings, Data Management trainings and etc., are held to build local professionals capacities. The surveillance will continue until April 2018 to have two year data.
Program expenses $3,207,872.00 
Grants and allocations made $1,542,738.00 
Program description The Cholera Vaccine Initiative (CHOVI) 3 project activities carried out in 2016 under CHOVI grant. Firstly, Euvichol : A bridging study to evaluate the safety and immunogenicity of thimerosal-free Euvichol produced in a 600L fermenter was conducted in 2016. The study started in May 2016, and a total of 442 participants were enrolled in this study. WHO PQ was obtained for 100L Euvichol in December 2015 and for 600L Euvichol without thiomersal in September 2016 respectively. Secondly, Cholvax trial and GMP support for Incepta : Production of 3 lots completed in March 2016. The study was started in May 2016, and enrolled a total of 2,052 participants from May to October 2016. Day 42 safety follow-up was completed in November 2016. Thirdly, Cholera surveillance in Malawi: Cholera surveillance is embarked in April 2016. Series of trainings such as lab trainings, Data Management trainings and etc., are held to build local professionals capacities. The surveillance will continue until April 2018 to have two year data. 
The Dengue Vaccine Initiative (DVI) has been paving the way for introduction of dengue vaccine through evidence generation, policy and access, regulatory, and advocacy activities. DVI has been conducting studies on dengue disease and economic burden through field studies in Thailand, Vietnam, Cambodia, Colombia, Burkina Faso, and Gabon. In 2015, DVI continued surveillance, serological surveys, and cost-of-illness survey in these countries. In addition, DVI made preparations for the launch of a new field site in Kenya. DVI convened the Americas Dengue Prevention Board Meeting in 2015 in Colombia. The meeting focused on providing technical consultation to policy makers and key stakeholders for dengue vaccine introduction in Latin America. In Nov 2015, DVI convened a meeting of national regulatory authorities (NRAs) from dengue endemic countries to provide technical consultation and discuss the status of regulatory approvals for dengue vaccine.
Program expenses  $4,005,864.00
Grants and allocations made  $2,169,518.00
Program description  The Dengue Vaccine Initiative (DVI) has been paving the way for introduction of dengue vaccine through evidence generation, policy and access, regulatory, and advocacy activities. DVI has been conducting studies on dengue disease and economic burden through field studies in Thailand, Vietnam, Cambodia, Colombia, Burkina Faso, and Gabon. In 2015, DVI continued surveillance, serological surveys, and cost-of-illness survey in these countries. In addition, DVI made preparations for the launch of a new field site in Kenya. DVI convened the Americas Dengue Prevention Board Meeting in 2015 in Colombia. The meeting focused on providing technical consultation to policy makers and key stakeholders for dengue vaccine introduction in Latin America. In Nov 2015, DVI convened a meeting of national regulatory authorities (NRAs) from dengue endemic countries to provide technical consultation and discuss the status of regulatory approvals for dengue vaccine.
Vaccine Development against MERS-CoV Since IVI launched the MERS Program in late 2015 with funding from the Samsung Life Public Welfare Foundation, IVI continues to work on accelerating the development of MERS vaccines, with the aim of demonstrating the safety and immunogenicity of two MERS vaccines in Phase II trials conducted in South Korea. IVI and GeneOne Life Sciences signed a Collaboration and Access Agreement to support GeneOnes MERS DNA vaccine candidate in late 2016, and Phase I/IIa clinical trials for GeneOnes vaccine were approved by the Korean Ministry of Food and Drug Safety (KMFDS) in 2017. The toxicity study, required by KMFDS as part of their IND approval, was initiated in Dec 2017. IVI also kept engaging with a donor and vaccine developers to select 2nd candidate MERS-CoV vaccine in addition to GeneOne DNA vaccine, through landscape analysis. Other than clinical studies, an epidemiological study was initiated in 2017 to develop and analyze a dynamic model of MERS-CoV transmission in Korea, which would support the Korean regulatory bodies to make effective strategies on MERS-CoV vaccination and vaccine stockpiling. BSL-3 facilities were re-certified in mid-2017 and would be operated for laboratory testing on MERS-CoV clinical samples.
Program expenses$3,744,627.00  
Grants and allocations made$1,955,450.00  
Program descriptionVaccine Development against MERS-CoV Since IVI launched the MERS Program in late 2015 with funding from the Samsung Life Public Welfare Foundation, IVI continues to work on accelerating the development of MERS vaccines, with the aim of demonstrating the safety and immunogenicity of two MERS vaccines in Phase II trials conducted in South Korea. IVI and GeneOne Life Sciences signed a Collaboration and Access Agreement to support GeneOnes MERS DNA vaccine candidate in late 2016, and Phase I/IIa clinical trials for GeneOnes vaccine were approved by the Korean Ministry of Food and Drug Safety (KMFDS) in 2017. The toxicity study, required by KMFDS as part of their IND approval, was initiated in Dec 2017. IVI also kept engaging with a donor and vaccine developers to select 2nd candidate MERS-CoV vaccine in addition to GeneOne DNA vaccine, through landscape analysis. Other than clinical studies, an epidemiological study was initiated in 2017 to develop and analyze a dynamic model of MERS-CoV transmission in Korea, which would support the Korean regulatory bodies to make effective strategies on MERS-CoV vaccination and vaccine stockpiling. BSL-3 facilities were re-certified in mid-2017 and would be operated for laboratory testing on MERS-CoV clinical samples.  
Vi-DT clinical development support for SK Chemicals We developed a typhoid conjugate vaccine using platform technology from the U.S. National Institutes of Health, conjugating the Salmonella Typhi Vi polysaccharide to diphtheria toxoid (Vi-DT). Conjugate vaccines have the advantage of conferring protection to infants (a high-risk group) against typhoid as well as generating T-cell-based immune responses. IVI transferred this technology to SK Chemicals in South Korea in 2013 and received grants from the Gates Foundation to work with SK Chemicals (IVI is leading clinical development). This collaboration aims to obtain vaccine licensure and then receive WHO prequalification for procurement in the Gavi/ UNICEF market. -Phase I clinical trial for SK Vi-DT was completed in Manila, the Philippines. There were 144 study participants enrolled. The trial showed no vaccine safety concerns and a 100% seroconversion rate. -Phase II clinical trials is in progress and exploratory steps for a Phase III trial have been undertaken.
Program expenses$3,343,014.00  
Grants and allocations made$1,981,519.00  
Program descriptionVi-DT clinical development support for SK Chemicals We developed a typhoid conjugate vaccine using platform technology from the U.S. National Institutes of Health, conjugating the Salmonella Typhi Vi polysaccharide to diphtheria toxoid (Vi-DT). Conjugate vaccines have the advantage of conferring protection to infants (a high-risk group) against typhoid as well as generating T-cell-based immune responses. IVI transferred this technology to SK Chemicals in South Korea in 2013 and received grants from the Gates Foundation to work with SK Chemicals (IVI is leading clinical development). This collaboration aims to obtain vaccine licensure and then receive WHO prequalification for procurement in the Gavi/ UNICEF market. -Phase I clinical trial for SK Vi-DT was completed in Manila, the Philippines. There were 144 study participants enrolled. The trial showed no vaccine safety concerns and a 100% seroconversion rate. -Phase II clinical trials is in progress and exploratory steps for a Phase III trial have been undertaken.  
Financial data
Expense categories (totals)
Sum (total functional expenses)$25,942,177.00$25,025,024.00$21,829,246.00
Program services (total functional expenses)$21,409,516.00$20,009,212.00$16,634,140.00
Management & general (total functional expenses)$4,011,044.00$4,412,207.00$4,369,115.00
Fundraising (total functional expenses)$521,617.00$603,605.00$825,991.00
Revenue
Total revenue$27,796,517.00$26,056,902.00$21,152,043.00
Program service revenue (total)$0.00$0.00$0.00
Revenue from contributions (total)$27,484,411.00$25,948,268.00$21,104,491.00
Revenue from noncash contributions$26,338.00 $18,669.00
Investment income$76,238.00$49,021.00$35,005.00
Total unrelated business revenue$0.00$0.00$0.00
Other revenue, current yr$235,868.00$59,613.00$12,547.00
Total revenue from grants, etc., current yr$27,484,411.00$25,948,268.00$21,104,491.00
Gross receipts$27,796,643.00$26,061,531.00$21,157,422.00
Sources of contributions
Revenue from fundraising events$28,754.00$35,059.00$44,483.00
Revenue from gov't grants$5,842,234.00$5,620,182.00$4,370,748.00
Revenue from all other contributions$21,613,423.00$20,293,027.00$16,689,260.00
Other types of revenue
Royalties (total)$0.00$0.00$0.00
Miscellaneous revenue (total)$235,735.00$63,086.00$15,859.00
Net revenue from gaming (total)$0.00$0.00$0.00
Income from dividends, interest, and similar investments$76,238.00$49,021.00$35,005.00
Net rental income$0.00$0.00$0.00
Net income from fundraising events$133.00$0.00$0.00
Net inventory sales (total)$0.00-$3,473.00-$3,312.00
Fees for services
Lobbying fees (total)$0.00$0.00$0.00
Legal fees (total)$170,761.00$66,330.00$59,865.00
Fundraising service fees (total)$0.00$0.00$0.00
General management fees (total)$0.00$0.00$0.00
Investment management fees (total)$0.00$0.00$0.00
Accounting service fees (total)$85,551.00$40,741.00$58,060.00
Assets and liabilities
Total assets$20,916,339.00$23,484,429.00$28,657,279.00
Total assets, beginning of year$23,484,429.00$28,657,279.00$29,405,974.00
Total liabilities$14,043,688.00$18,538,434.00$24,922,927.00
Total liabilities, beginning of year$18,538,434.00$24,922,927.00$24,513,481.00
Pledges & accounts receivable, net$81,190.00$27,359.00$343,578.00
Loans & receivables from key persons$140,545.00$229,190.00$113,417.00
Net assets$6,872,651.00$4,945,995.00$3,734,352.00
Net assets, beginning of year$4,945,995.00$3,734,352.00$4,892,493.00
Other liabilities$1,016,551.00$0.00$0.00
Bond liabilities$0.00$0.00$0.00
Intangible assets$0.00$0.00$0.00
Other assets$4,246.00$4,246.00$4,247.00
Investments: other securities$0.00$0.00$0.00
Investments: publicly traded securities$0.00$0.00$0.00
Cash: non-interest bearing$0.00$0.00$0.00
Cash: non-interest bearing, beginning of year$0.00$0.00$0.00
Investments: program-related$0.00$0.00$0.00
Escrow or custodial account liability$0.00$0.00$0.00
Loans and other payables to key persons$0.00$0.00$0.00
Grants payable$0.00$0.00$0.00
Inventories for sale or use$0.00$0.00$0.00
Other financial variables
Revenue less expenses$1,854,340.00$1,031,878.00-$677,203.00
Advertising (total)$0.00$0.00$0.00
Savings & temp cash investment$19,061,316.00$21,637,741.00$26,528,150.00
Accounts receivable, net$24,709.00$19,126.00$8,171.00
Prepaid expenses & deferred charges$229,986.00$407,788.00$369,155.00
Accounts payable & accrued expenses$1,469,522.00$2,734,583.00$1,843,335.00
Deferred revenue$11,557,615.00$15,803,851.00$23,079,592.00
Unsecured notes & loans to unrelated parties$0.00$0.00$0.00
Secured mortgages and notes payable$0.00$0.00$0.00
Total net assets or fund balances$6,872,651.00$4,945,995.00$3,734,352.00
Depreciation, depletion, amortization$207,468.00$321,993.00$237,281.00
Payment to affiliates$0.00$0.00$0.00
Governance and accountability
Number of voting members151210
Number of independent voting members10119
Financial sheets auditedTrueTrueTrue
Relationships among key personnelTrueTrueTrue
Tax year start date2017-01-012016-01-012015-01-01
Tax year end date2017-12-312016-12-312015-12-31
Accounting methodAccrualAccrualAccrual
Indicators for schedules (selected)
Outstanding loan to key person or disqualified personTrueTrueTrue
Grants to domestic org/gov't >$5kTrueTrueTrue
Metadata about the filing
E-return type990990990
Date e-filing submitted2018-09-242017-10-122016-11-02
IRS schema version2017v2.32016v3.12015v2.1
Filing identifier201812089349300206201741939349300029201632019349300433
Use these data in your project Benchmark this organization against its peers